文献速递重症综合管理与镇静镇痛心脑血管急症复苏、休克与脓毒症

心脏骤停后脑外器官衰竭与1年生存及医疗相关费用的关联:一项观察性数据库研究

Association of extracerebral organ failure with 1-year survival and healthcare-associated costs after cardiac arrest: an observational database study.
PubMed 文献 · Crit Care · 2019-02-28
一句话结论心脏骤停后24小时脑外SOFA评分每增1分与1年死亡风险升高相关(OR 1.16,95%CI 1.14-1.18),并与存活者总费用增加相关。

基于芬兰五所大学医院ICU 2003年1月1日至2013年12月31日的全国登记数据,纳入5814例成人心脏骤停患者,其中2401例1年后存活。1年存活者24小时脑外SOFA评分中位数为6(5-8),死亡者为7(5-10)。校正年龄和既往自理独立性后,24小时脑外SOFA评分每增1分,1年死亡OR为1.16(95%CI 1.14-1.18)。1年存活者医疗相关费用中位数为47000欧元(28000-75000欧元),死亡者为12000欧元(6600-25000欧元);评分每增1分,存活者总医疗相关费用增加4400欧元(95%CI 3300-5500欧元)。

要点

  • 成人心脏骤停ICU患者中,24小时脑外SOFA评分每增1分,1年死亡OR为1.16(95%CI 1.14-1.18),校正年龄和既往自理独立性。
  • 1年存活者24小时脑外SOFA评分中位数6(5-8),死亡者7(5-10)。
  • 1年存活者医疗相关费用中位数47000欧元(28000-75000欧元),死亡者12000欧元(6600-25000欧元)。
  • 24小时脑外SOFA评分每增1分,与存活者总医疗相关费用增加4400欧元(95%CI 3300-5500欧元)及每日存活费用增加170欧元(95%CI 150-190欧元)相关。
  • 作者认为评估改善预后和优化资源的干预措施时应考虑脑外器官功能障碍。

适用人群与场景

  • 2003年1月1日至2013年12月31日在芬兰五所大学医院ICU治疗的成人心脏骤停患者。

研究设计与关键结果

  • 观察性数据库研究,纳入5814例成人心脏骤停患者,2401例1年后存活。
  • 1年存活者24小时脑外SOFA评分中位数6(IQR 5-8),死亡者7(IQR 5-10)。
  • 校正年龄和既往自理独立性后,24小时脑外SOFA评分每增1分,1年死亡OR为1.16(95%CI 1.14-1.18)。
  • 1年存活者医疗相关费用中位数47000欧元(IQR 28000-75000欧元),死亡者12000欧元(IQR 6600-25000欧元)。
  • 校正年龄和既往自理独立性后,24小时脑外SOFA评分每增1分,存活者总医疗相关费用增加4400欧元(95%CI 3300-5500欧元),每日存活费用增加170欧元(95%CI 150-190欧元)。

证据类型、等级与局限

  • 观察性数据库研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,脑外器官功能障碍与ICU治疗的心脏骤停患者的长期结局和总医疗相关费用相关,在评估改善预后和优化资源的干预措施时应予以考虑。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Organ dysfunction is common after cardiac arrest and associated with worse short-term outcome, but its impact on long-term outcome and treatment costs is unknown.

METHODS: We used nationwide registry data from the intensive care units (ICU) of the five Finnish university hospitals to evaluate the association of 24-h extracerebral Sequential Organ Failure Assessment (24h-EC-SOFA) score with 1-year survival and healthcare-associated costs after cardiac arrest. We included adult cardiac arrest patients treated in the participating ICUs between January 1, 2003, and December 31, 2013. We acquired the confirmed date of death from the Finnish Population Register Centre database and gross 1-year healthcare-associated costs from the hospital billing records and the database of the Finnish Social Insurance Institution.

RESULTS: A total of 5814 patients were included in the study, and 2401 were alive 1 year after cardiac arrest. Median (interquartile range (IQR)) 24h-EC-SOFA score was 6 (5-8) in 1-year survivors and 7 (5-10) in non-survivors. In multivariate regression analysis, adjusting for age and prior independency in self-care, the 24h-EC-SOFA score had an odds ratio (OR) of 1.16 (95% confidence interval (CI) 1.14-1.18) per point for 1-year mortality. Median (IQR) healthcare-associated costs in the year after cardiac arrest were €47,000 (€28,000-75,000) in 1-year survivors and €12,000 (€6600-25,000) in non-survivors. In a multivariate linear regression model adjusting for age and prior independency in self-care, an increase of one point in the 24h-EC-SOFA score was associated with an increase of €170 (95% CI €150-190) in the cost per day alive in the year after cardiac arrest. In the same model, an increase of one point in the 24h-EC-SOFA score was associated with an increase of €4400 (95% CI €3300-5500) in the total healthcare-associated costs in 1-year survivors.

CONCLUSIONS: Extracerebral organ dysfunction is associated with long-term outcome and gross healthcare-associated costs of ICU-treated cardiac arrest patients. It should be considered when assessing interventions to improve outcomes and optimize the use of resources in these patients.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Pekkarinen PT, Bäcklund M, Efendijev I, et al. Association of extracerebral organ failure with 1-year survival and healthcare-associated costs after cardiac arrest: an observational database study. Crit Care. 2019. PMID: 30819234. doi:10.1186/s13054-019-2359-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。